LNCaP-FGC Xenograft Model Service for Prostate Cancer

The LNCaP-FGC cell line provides a refined and highly consistent in vivo platform for investigating the molecular mechanisms of androgen-sensitive prostate cancer. As a premier pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision LNCaP-FGC Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your prostate cancer drug discovery and development pipeline.

Overview of LNCaP-FGC Xenograft Model for Prostate Cancer

The LNCaP-FGC (Fell Colony) xenograft model is an established in vivo translational system utilized in oncology research for the study of human prostate adenocarcinoma. By transplanting LNCaP-FGC cells into immunodeficient rodent hosts, this model effectively reproduces the androgen-responsive growth characteristics, histopathological architecture, and PSA-secreting patterns typical of hormone-sensitive human prostate malignancies.

Biologically, the LNCaP-FGC model is characterized by a high degree of phenotypic stability and reliable androgen receptor (AR) expression, making it a critical system for evaluating the efficacy of anti-androgen therapies, hormonal inhibitors, and novel agents targeting the AR signaling axis. The model maintains the essential molecular and proliferative features of the primary LNCaP line while offering improved consistency in tumor take rates and growth kinetics in vivo. Consequently, the LNCaP-FGC model is extensively deployed in pre-clinical screening programs to assess the anti-tumor potency of therapeutic candidates in a physiologically relevant environment.

Cell Line Information: LNCaP-FGC

The LNCaP-FGC cell line is a subline derived from the parental LNCaP cell line, selected for enhanced uniformity and stability. These cells exhibit robust growth characteristics in vitro and retain the androgen-dependent nature of the original lineage, making them a standard tool for reproducible prostate cancer research.

Our Services

Workflow of LNCaP-FGC Xenograft Model Construction

• Cell Culture & Quality Control: Human LNCaP-FGC cells are expanded in vitro using certified nutrient media under optimized physiological conditions. STR authentication and mycoplasma screening are performed prior to inoculation to ensure absolute genetic integrity and purity.
• Host Selection & Preparation: Immunodeficient rodent models are utilized for tumor engraftment, with all animals maintained in a controlled, pathogen-free environment to ensure physiological stability and consistency throughout the study.
• Precision Inoculation: A calibrated suspension of high-viability LNCaP-FGC cells is prepared, often supplemented with an extracellular matrix (e.g., Matrigel) to optimize take efficiency. Cells are inoculated in vivo via subcutaneous injection into the host flank to facilitate the development of a measurable, solid tumor.
• Longitudinal Monitoring: Tumor size is measured systematically using digital calipers to monitor volume progression. Animal health, activity, and body weight are recorded periodically to document systemic tolerance and clinical status.
• Randomization & Treatment: Once solid tumors reach a predefined, statistically significant volume, animals are randomized into matched cohorts to ensure baseline parity before the initiation of customized therapeutic dosing regimens.

Fig 1. LNCaP-FGC Xenograft Model Construction Workflow

Case Study - LNCaP-FGC Xenograft Model Development

A pre-clinical validation study was conducted using the LNCaP-FGC xenograft model to evaluate the therapeutic efficacy of a novel AR antagonist. Following the successful subcutaneous inoculation of LNCaP-FGC cells into immunodeficient mice, the host animals developed firm, rapidly growing solid tumors. The treatment group demonstrated a clear, statistically significant inhibition of tumor growth compared to the vehicle-treated control group, confirming the model's sensitivity and reliability for screening novel hormonal therapies in a prostate cancer research setting.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing specialized prostate cancer lineages, providing highly reproducible in vivo translational platforms for complex hormonal-resistance research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive tumor growth metrics and statistical validations.

Contact us

Accelerating your prostate cancer drug pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our LNCaP-FGC platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.